Flibanserin, a non-hormonal drug for the treatment of hypoactive sexual desire disorder (HSDD) in post-menopausal women, has been resubmitted for a New Drug Application, the drug’s maker, Sprout Pharmaceuticals, of Raleigh, NC, announced.
FDA Approval Sought for Female Sexual Disorder Drug
